Nevirapine exposure with WHO pediatric weight band dosing: Enhanced therapeutic concentrations predicted based on extensive international pharmacokinetic experience

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 10, 2012, Pages 5374-5380

  Nikanjam, Mina ^a   Kabamba, Desiré ^b   Cressey, Tim R ^c,d,e   Burger, David ^f   Aweek, Francesca T ^g   Acosta, Edward P ^h   Spector, Stephen A ^a,i   Capparelli, Edmund V ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY TEACHING HOSPITAL   (Zambia)

^c CHIANG MAI UNIVERSITY   (Thailand)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (France)

^f RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

ⁱ RADY CHILDREN'S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2B6; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADOLESCENT; ADULT; AGE; ARTICLE; CHILD; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DOSE COMPARISON; DRUG EXPOSURE; DRUG FORMULATION; FOOD AND DRUG ADMINISTRATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INFANT; MAJOR CLINICAL STUDY; MONTE CARLO METHOD; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PREDICTOR VARIABLE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; WEIGHT BAND DOSING; WORLD HEALTH ORGANIZATION;

ADOLESCENT; ANTI-HIV AGENTS; CHILD; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HIV INFECTIONS; HUMANS; INFANT; INFANT, NEWBORN; MALE; NEVIRAPINE; WORLD HEALTH ORGANIZATION; YOUNG ADULT;

EID: 84866307391     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00842-12     Document Type: Article

References (27)

1. Capparelli EV, et al. 2008. Chronic administration of nevirapine during pregnancy: impact of pregnancy on pharmacokinetics. HIV Med. 9:214-220. (Pubitemid 351467794)
2. Capparelli EV, et al. 2001. Pharmacokinetics of nelfinavir in human immunodeficiency virus-infected infants. Pediatr. Infect. Dis. J. 20:746-751. (Pubitemid 32758015)
3. Chokephaibulkit K, et al. 2011. Pharmacokinetics and safety of a new paediatric fixed-dose combination of zidovudine/lamivudine/nevirapine in HIV-infected children. Antivir. Ther. 16:1287-1295.
4. Chou M, et al. 2010. Population pharmacokinetic-pharmacogenetic study of nevirapine in HIV-infected Cambodian patients. Antimicrob. Agents Chemother. 54:4432-4439.
5. Cooper CL, van Heeswijk RP. 2007. Once-daily nevirapine dosing: a pharmacokinetics, efficacy and safety review. HIV Med. 8:1-7. (Pubitemid 46117834)
6. Dailly E, et al. 2009. Influence of darunavir coadministration on nevirapine pharmacokinetics in HIV-infected patients: a population approach. HIV Med. 10:586-589.
7. de Bethune MP. 2010. Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: a review of the last 20 years (1989-2009). Antiviral Res. 85:75-90.
8. de Maat MM, et al. 2002. Population pharmacokinetics of nevirapine in an unselected cohort of HIV-1-infected individuals. Br. J. Clin. Pharmacol. 54:378-385.
9. de Maat MM, et al. 2004. Race is not associated with nevirapine pharmacokinetics. Ther. Drug Monit. 26:456-458.
10. Duong M, et al. 2005. Low trough plasma concentrations of nevirapine associated with virologic rebounds in HIV-infected patients who switched from protease inhibitors. Ann. Pharmacother. 39:603-609. (Pubitemid 40396611)
11. Elsherbiny D, et al. 2009. Population pharmacokinetics of nevirapine in combination with rifampicin-based short course chemotherapy in HIV- and tuberculosis-infected South African patients. Eur. J. Clin. Pharmacol. 65:71-80.
12. Floren LC, et al. 2003. Nelfinavir pharmacokinetics in stable human immunodeficiency virus-positive children: Pediatric AIDS Clinical Trials Group Protocol 377. Pediatrics 112:e220-e227.
13. Kappelhoff BS, et al. 2005. Pharmacokinetics of nevirapine: once-daily versus twice-daily dosing in the 2NN study. HIV Clin. Trials 6:254-261. (Pubitemid 43025156)
14. King JR, Kimberlin DW, Aldrovandi GM, Acosta EP. 2002. Antiretroviral pharmacokinetics in the paediatric population: a review. Clin. Pharmacokinet. 41:1115-1133. (Pubitemid 35398689)
15. King JR, et al. 2005. Efficacy, tolerability and pharmacokinetics of two nelfinavir-based regimens in human immunodeficiency virus-infected children and adolescents: pediatric AIDS clinical trials group protocol 403. Pediatr. Infect. Dis. J. 24:880-885. (Pubitemid 41475922)
16. Kovacs A, et al. 2005. Immune reconstitution after receipt of highly active antiretroviral therapy in children with advanced or progressive HIV disease and complete or partial viral load response. J. Infect. Dis. 192:296-302. (Pubitemid 40993399)
17. L'Homme RF, et al. 2008. Nevirapine, stavudine and lamivudine pharmacokinetics in African children on paediatric fixed-dose combination tablets. AIDS 22:557-565. (Pubitemid 351640588)
18. Luzuriaga K, et al. 1997. Combination treatment with zidovudine, didanosine, and nevirapine in infants with human immunodeficiency virus type 1 infection. N. Engl. J. Med. 336:1343-1349. (Pubitemid 27208617)
19. Luzuriaga K, et al. 1996. Pharmacokinetics, safety, and activity of nevirapine in human immunodeficiency virus type 1-infected children. J. Infect. Dis. 174:713-721. (Pubitemid 26325885)
20. Milinkovic A, Martinez E. 2004. Nevirapine in the treatment of HIV. Expert Rev. Anti Infect. Ther. 2:367-373. (Pubitemid 38745097)
21. Molto J, et al. 2008. Once- or twice-daily dosing of nevirapine in HIV-infected adults: a population pharmacokinetics approach. J. Antimicrob. Chemother. 62:784-792.
22. Penzak SR, et al. 2007. Cytochrome P450 2B6 (CYP2B6) G516T influences nevirapine plasma concentrations in HIV-infected patients in Uganda. HIV Med. 8:86-91. (Pubitemid 46390844)
23. Pollock L, et al. 2009. Pharmacokinetics of nevirapine in HIV-infected children with and without malnutrition receiving divided adult fixed-dose combination tablets. J. Antimicrob. Chemother. 64:1251-1259.
24. Saitoh A, et al. 2007. CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children. AIDS 21:2191-2199. (Pubitemid 350287217)
25. U. S. Food and Drug Administration. 2010. Viramune (nevirapine) January prescribing information. http://www.accessdata.fda.gov/drugsatfda-docs/label/ 2010/020933s022, 020636s032lbl.pdf.
26. Vanprapar N, et al. 2010. A chewable pediatric fixed-dose combination tablet of stavudine, lamivudine, and nevirapine: pharmacokinetics and safety compared with the individual liquid formulations in human immunodeficiency virus-infected children in Thailand. Pediatr. Infect. Dis. J. 29:940-944.
27. Zhou XJ, et al. 1999. Population pharmacokinetics of nevirapine, zidovudine, and didanosine in human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. 43:121-128.